CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
CancerVax, Inc. has developed a 'Smart mRNA' platform designed to disguise cancer cells as common viral infections, triggering the body's pre-existing T-cell immunity to attack the tumor. The company has successfully completed the design and in-vitro validation of this polyepitope construct.
Why it matters
This represents a potential breakthrough in cancer immunotherapy by leveraging existing population immunity to create a more effective and broadly applicable treatment.
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity
The article reports on a corporate press release regarding medical technology development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in